<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02120157</url>
  </required_header>
  <id_info>
    <org_study_id>J13161</org_study_id>
    <secondary_id>NA_00091665</secondary_id>
    <nct_id>NCT02120157</nct_id>
  </id_info>
  <brief_title>Trial of Myeloablative Conditioning &amp; Transplantation of Partially Human Leukocyte Antigen (HLA)-Mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies</brief_title>
  <official_title>Pediatric Blood &amp; Marrow Transplant Consortium (PBMTC) Multi-center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched T Cell Replete Bone Marrow With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a multi-institutional phase II haplo-identical T cell replete bone marrow&#xD;
      transplant (BMT) study in children with high-risk leukemia. The myeloablative conditioning&#xD;
      regimen prescribed will be Total body irradiation (TBI)-based for lymphoid leukemia and&#xD;
      busulfan-based for myeloid leukemia. Our goal is to establish an easily exportable,&#xD;
      inexpensive platform for haplotransplantation that has a safety profile equivalent to matched&#xD;
      related and unrelated BMTs. The primary objective will be to estimate the incidence of&#xD;
      6-month non-relapse mortality (NRM), hypothesizing that NRM is &lt; 18%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II prospective study designed to evaluate the incidence of 6 month non-&#xD;
      relapse mortality, safety, and feasibility of haploidentical bone marrow transplantation&#xD;
      (BMT) after myeloablative conditioning with post-transplant Cy. Conditioning regimens include&#xD;
      a total body irradiation (TBI)-based prep for lymphoid leukemias and a chemotherapy based&#xD;
      prep for myeloid leukemias.&#xD;
&#xD;
      To estimate the incidence of non-relapse mortality at 180 days following myeloablative&#xD;
      haploidentical BMT for children and young adults with high risk hematologic malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2015</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Mortality</measure>
    <time_frame>Day 180</time_frame>
    <description>Number of patients with non-relapse mortality at 180 days following myeloablative, HLA-mismatched bone marrow transplant (BMT) for patients with high risk hematologic malignancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Donor Cell Engraftment</measure>
    <time_frame>Day 60</time_frame>
    <description>Number of Participants with Donor Cell Engraftment at Day 60 following myeloablative, HLA-mismatched BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft Versus Host Disease (GVHD) Grades 2-4 and Grades 3-4</measure>
    <time_frame>2 Years</time_frame>
    <description>Number of participants with acute GVHD grades 2-4 and grades 3-4. Acute GVHD Grade 0= no skin, liver or gut involvement; Grade I= Stage 1-2 skin involvement, no liver or gut involvement; Grade II= Stage 3 skin, and/or Stage 1 liver, and/or Stage 1 gut involvement; Grade III= Stage 3 or no skin involvement, Stage 2-3 liver or Stage 2-4 gut involvement; Grade IV= Stage 4 skin or Stage 4 liver involvement. Skin involvement is staged as follows: 1= rash &lt;25% body surface area (BSA), 2= rash 25-50% BSA, 3= rash &gt;50% BSA, 4= generalized erythroderma with bullae. Gastrointestinal (gut) involvement is staged as follows: 1= diarrhea 500-1000 mL/day or 280-555 mL/m^2, or persistent nausea; 2= diarrhea 1000-1499 mL/day or 556-833 mL/m^2; 3= diarrhea &gt;1500 mL/day or &gt;833 mL/m^2; 4= large volume of diarrhea and severe abdominal pain with/without ileus. Liver involvement is staged as follows: 1= bilirubin 2-3mg/dL, 2= bilirubin 3-6mg/dL, 3= 6-15mg/dL, bilirubin &gt;15 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary and Secondary Graft Failure</measure>
    <time_frame>2 Years</time_frame>
    <description>Number of participants with primary and secondary graft failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid and Non-steroid Immunosuppressants</measure>
    <time_frame>Two Years</time_frame>
    <description>Characterize the duration of use, number, and type of steroid and non-steroid immunosuppressants used to treat GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Estimate overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), event-free survival, and relapse-free GVHD-free survival (GRFS) in patients receiving myeloablative, HLA-mismatched BMT for patients with high risk hematologic malignancies at 1 year and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic and Non-hematologic Toxicities</measure>
    <time_frame>Two Years</time_frame>
    <description>Assess hematologic and non-hematologic toxicities of myeloablative haploidentical BMT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution</measure>
    <time_frame>Two Years</time_frame>
    <description>Characterize immune reconstitution post myeloablative haploidentical BMT with Post transplantation cyclophosphamide (PT/Cy).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Myeloablative Conditioning</condition>
  <condition>HLA-mismatched Bone Marrow Transplantation</condition>
  <condition>Graft Survival</condition>
  <condition>Transplantation, Bone Marrow</condition>
  <arm_group>
    <arm_group_label>1: Acute Lymphoblastic Leukemia/Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days*&#xD;
Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV+&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV# Mesna 40 mg/kg Ideal body weight (IBW)/day IV#&#xD;
Day +5: Begin tacrolimus 0.015mg/kg/ IBW dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35 Discontinue MMF&#xD;
Day +60 Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Acute Lymphocytic Leukemia/Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV+&#xD;
Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV&#xD;
Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35: Discontinue MMF&#xD;
Day +60: Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Chemotherapy administration</description>
    <arm_group_label>1: Acute Lymphoblastic Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>2: Acute Lymphocytic Leukemia/Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>Radiation Therapy</description>
    <arm_group_label>2: Acute Lymphocytic Leukemia/Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Chemotherapy Administered</description>
    <arm_group_label>1: Acute Lymphoblastic Leukemia/Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Unmanipulated Bone Marrow</intervention_name>
    <description>Bone Marrow Transplant</description>
    <arm_group_label>1: Acute Lymphoblastic Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>2: Acute Lymphocytic Leukemia/Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Immunosuppressive Drug Administered</description>
    <arm_group_label>1: Acute Lymphoblastic Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>2: Acute Lymphocytic Leukemia/Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Immunosuppressive Drug Administered</description>
    <arm_group_label>1: Acute Lymphoblastic Leukemia/Lymphoma</arm_group_label>
    <arm_group_label>2: Acute Lymphocytic Leukemia/Lymphoma</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient age 0.5-25years&#xD;
&#xD;
          -  Patients must have a first-degree related donor or half-sibling who is at minimum HLA&#xD;
             haploidentical. The donor and recipient must be identical at at least one allele of&#xD;
             each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1. A&#xD;
             minimum match of 5/10 is therefore required, and will be considered sufficient&#xD;
             evidence that the donor and recipient share one HLA haplotype.&#xD;
&#xD;
          -  An unrelated donor search is not required for a patient to be eligible for this&#xD;
             protocol, or a donor search and donor mobilization may be abandoned if the clinical&#xD;
             situation dictates an urgent transplant. Clinical urgency is defined as 6-8 weeks from&#xD;
             referral to transplant or a low-likelihood of finding a matched, unrelated donor.&#xD;
             Patients with an eligible HLA-matched RELATED should not be enrolled on this trial.&#xD;
&#xD;
          -  Patients must have at least one of the following high-risk conditions listed below:&#xD;
&#xD;
          -  Acute lymphocytic leukemia (ALL) in CR1* as defined by at least one of the following:&#xD;
&#xD;
        hypodiploidy, induction failure,Minimal residual disease (MRD) after consolidation&#xD;
&#xD;
        - Acute myeloid leukemia (AML) in CR1 with high risk features defined as: High allelic&#xD;
        ratio FLT3/ITD+, Monosomy 7, Del (5q), Standard risk cytogenetics with positive minimal&#xD;
        residual disease at the end of Induction I chemotherapy (for patients being treated on or&#xD;
        according to Children's Oncology Group (COG) AAML1031 study who have had MRD studies sent&#xD;
        to Seattle or performed at their local institution where the flow assay is sensitive enough&#xD;
        to detect &gt; 0.1% blasts)&#xD;
&#xD;
          -  Acute Leukemia in 2nd or subsequent CR (CR&gt;2)&#xD;
&#xD;
          -  Mixed phenotype/Undifferentiated Leukemia in 1st or subsequent CR*&#xD;
&#xD;
          -  Secondary or therapy related leukemia in CR &gt; 1&#xD;
&#xD;
          -  Natural Killer (NK) cell lymphoblastic leukemia CR &gt; 1&#xD;
&#xD;
          -  Myelodysplastic syndrome (MDS)&#xD;
&#xD;
          -  Juvenile myelomonocytic leukemia (JMML) (patients are eligible if they are not&#xD;
             eligible for COG1221 study)&#xD;
&#xD;
          -  Prior transplant eligible if &lt; 18yo, &gt;6 months has elapsed since BMT, and patient is&#xD;
             off immunosuppression for &gt; 3 months with no Graft versus host disease (GVHD)&#xD;
&#xD;
          -  No known active Central nervous system (CNS) involvement or extramedullary involvement&#xD;
             by malignancy. Such disease treated into remission is permitted.&#xD;
&#xD;
          -  Acute Leukemia - Remission is defined as morphology with &lt; 5% blasts with no&#xD;
             morphological characteristics of acute leukemia (e.g., Auer Rods) in a bone marrow&#xD;
             with &gt; 20% cellularity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor cardiac function: left ventricular ejection fraction &lt;45% as determined by&#xD;
             Multigated acquisition scan (MUGA) or Echocardiogram (ECHO). For pediatric patients&#xD;
             Left ventricular ejection fraction (LVEF) &lt;45% or a shortening fraction below normal&#xD;
             limits for age.&#xD;
&#xD;
          -  Symptomatic pulmonary disease. Poor pulmonary function: Forced expiratory volume&#xD;
             (FEV1), Forced vital capacity (FVC), and Diffusing capacity for carbon monoxide (DLCO)&#xD;
             &lt;50% predicted (corrected for hemoglobin) for patients who have not received thoracic&#xD;
             or mantle irradiation. For patients who have received thoracic or mantle irradiation,&#xD;
             FEV1 and FVC &lt;70% predicted or DLCO &lt; 50 of predicted. For children unable to perform&#xD;
             Pulmonary function tests (PFTs) because of developmental stage pulse oximetry &lt; 92% on&#xD;
             Room air (RA).&#xD;
&#xD;
          -  Poor liver function: bilirubin &gt;2 mg/dl (not due to hemolysis, Gilbert's or primary&#xD;
             malignancy). Alanine aminotransferase (ALT) or Aspartate transaminase (AST) &gt; 3 x&#xD;
             laboratory upper normal limits.&#xD;
&#xD;
          -  Poor renal function: Creatinine &gt;2.0mg/dl or creatinine clearance (calculated&#xD;
             creatinine clearance is permitted) &lt; 60 mL/min based on Traditional Cockcroft-Gault&#xD;
             formula: 140 - age (yrs) x Smaller of Actual Weight vs. Ideal Body Weight (kg) / 72 x&#xD;
             Serum creatinine (mg/dl) Multiply by another factor of 0.85 if female Intended for&#xD;
             ages 18-110, serum creatinine 0.6-7 mg/dl For patients &lt;18 years: creatinine clearance&#xD;
             (CrCl) will be estimated by the Schwartz formula. A measured CrCl or a Glomerular&#xD;
             filtration rate (GFR) may be substituted to determine the subject's CrCl.&#xD;
&#xD;
          -  Schwartz equation: CrCl (ml/min/1.73m2)=[length (cm) x k] /serum creatinine K = 0.45&#xD;
             for infants 1 to 52 weeks old k = 0.55 for children 1 to 13 years old k = 0.55 for&#xD;
             adolescent females 13-18 years old k = 0.7 for adolescent males 13-18 years old&#xD;
&#xD;
          -  HIV-positive&#xD;
&#xD;
          -  Positive leukocytotoxic crossmatch Specifically, complement dependent cytotoxicity and&#xD;
             flow cytometric crossmatch assays must be negative, and the mean fluorescence&#xD;
             intensity (MFI) of any anti-donor HLA antibody by solid phase immunoassay should be&#xD;
             &lt;3000. Consult with PI for the clinical significance of any anti-donor antibody.&#xD;
&#xD;
          -  Women of childbearing potential who currently are pregnant (HCG+) or who are not&#xD;
             practicing adequate contraception or who are breastfeeding&#xD;
&#xD;
          -  Uncontrolled viral, bacterial, or fungal infections (currently taking medication and&#xD;
             have progression of clinical symptoms)&#xD;
&#xD;
          -  Patients with symptoms consistent with Respiratory syncytial virus (RSV), influenza A,&#xD;
             B, or parainfluenza at the time of enrollment will be assayed for the above viruses&#xD;
             and if positive are not eligible for the trial until they are no longer symptomatic&#xD;
             (patients may have continued assay positivity for a period of time post resolution of&#xD;
             symptoms secondary to the nature of the assay&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Symons, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>SKCCC Johns Hopkins Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Alfred I. DuPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital Johns Hopkins Medicine</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2014</study_first_posted>
  <results_first_submitted>March 28, 2019</results_first_submitted>
  <results_first_submitted_qc>March 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2019</results_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Juvenile myelomonocytic leukemia</keyword>
  <keyword>Treatment related leukemia</keyword>
  <keyword>Biphenotypic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02120157/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Three patients screen failed due to: One patient could not report on whether the marrow is cellular or at least 20 percent cellularity, one patient had poor liver function, and the one patient's Alanine aminotransferase (ALT) was over the study limit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1: Acute Lymphoblastic Leukemia/Lymphoma</title>
          <description>Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days*&#xD;
Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV+&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV# Mesna 40 mg/kg ideal body weight (IBW)/day IV#&#xD;
Day +5: Begin tacrolimus 0.015mg/kg/ IBW dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35 Discontinue MMF&#xD;
Day +60 Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus&#xD;
Cyclophosphamide: Chemotherapy administration&#xD;
Busulfan: Chemotherapy Administered&#xD;
Unmanipulated Bone Marrow: Bone Marrow Transplant&#xD;
Tacrolimus: Immunosuppressive Drug Administered&#xD;
Mycophenolate mofetil: Immunosuppressive Drug Administered</description>
        </group>
        <group group_id="P2">
          <title>2: Acute Lymphocytic Leukemia/Lymphoma</title>
          <description>Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV+&#xD;
Days -3 through -1: Total body irradiation (TBI) 200 Centigray (cGy) 2 times day for 3 days&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV&#xD;
Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with max daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35: Discontinue MMF&#xD;
Day +60: Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus&#xD;
Cyclophosphamide: Chemotherapy administration&#xD;
TBI: Radiation Therapy&#xD;
Unmanipulated Bone Marrow: Bone Marrow Transplant&#xD;
Tacrolimus: Immunosuppressive Drug Administered&#xD;
Mycophenolate mofetil: Immunosuppressive Drug Administered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 180 Days</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Undergoing Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft Failure before Day 100</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1: Acute Lymphoblastic Leukemia/Lymphoma</title>
          <description>Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days*&#xD;
Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV+&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV# Mesna 40 mg/kg IBW/day IV#&#xD;
Day +5: Begin tacrolimus 0.015mg/kg/ IBW dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35 Discontinue MMF&#xD;
Day +60 Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus&#xD;
Cyclophosphamide: Chemotherapy administration&#xD;
Busulfan: Chemotherapy Administered&#xD;
Unmanipulated Bone Marrow: Bone Marrow Transplant&#xD;
Tacrolimus: Immunosuppressive Drug Administered&#xD;
Mycophenolate mofetil: Immunosuppressive Drug Administered</description>
        </group>
        <group group_id="B2">
          <title>2: Acute Lymphocytic Leukemia/Lymphoma</title>
          <description>Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV+&#xD;
Days -3 through -1: TBI 200 cGy twice a day for 3 days&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV&#xD;
Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35: Discontinue MMF&#xD;
Day +60: Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus&#xD;
Cyclophosphamide: Chemotherapy administration&#xD;
TBI: Radiation Therapy&#xD;
Unmanipulated Bone Marrow: Bone Marrow Transplant&#xD;
Tacrolimus: Immunosuppressive Drug Administered&#xD;
Mycophenolate mofetil: Immunosuppressive Drug Administered</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="1" upper_limit="23"/>
                    <measurement group_id="B2" value="13" lower_limit="1" upper_limit="23"/>
                    <measurement group_id="B3" value="12" lower_limit="1" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Mortality</title>
        <description>Number of patients with non-relapse mortality at 180 days following myeloablative, HLA-mismatched bone marrow transplant (BMT) for patients with high risk hematologic malignancies</description>
        <time_frame>Day 180</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1: Acute Lymphoblastic Leukemia/Lymphoma</title>
            <description>Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days*&#xD;
Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV+&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV# Mesna 40 mg/kg IBW/day IV#&#xD;
Day +5: Begin tacrolimus 0.015mg/kg/ IBW dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35 Discontinue MMF&#xD;
Day +60 Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus&#xD;
Cyclophosphamide: Chemotherapy administration&#xD;
Busulfan: Chemotherapy Administered&#xD;
Unmanipulated Bone Marrow: Bone Marrow Transplant&#xD;
Tacrolimus: Immunosuppressive Drug Administered&#xD;
Mycophenolate mofetil: Immunosuppressive Drug Administered</description>
          </group>
          <group group_id="O2">
            <title>2: Acute Lymphocytic Leukemia/Lymphoma</title>
            <description>Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h times 2 days+Mesna 40 mg/kg/day IV+&#xD;
Days -3 through -1: TBI 200 cGy twice a day for 3 days&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV&#xD;
Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35: Discontinue MMF&#xD;
Day +60: Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus&#xD;
Cyclophosphamide: Chemotherapy administration&#xD;
TBI: Radiation Therapy&#xD;
Unmanipulated Bone Marrow: Bone Marrow Transplant&#xD;
Tacrolimus: Immunosuppressive Drug Administered&#xD;
Mycophenolate mofetil: Immunosuppressive Drug Administered</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Mortality</title>
          <description>Number of patients with non-relapse mortality at 180 days following myeloablative, HLA-mismatched bone marrow transplant (BMT) for patients with high risk hematologic malignancies</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Donor Cell Engraftment</title>
        <description>Number of Participants with Donor Cell Engraftment at Day 60 following myeloablative, HLA-mismatched BMT.</description>
        <time_frame>Day 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1: Acute Lymphoblastic Leukemia/Lymphoma</title>
            <description>Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days*&#xD;
Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV+&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV# Mesna 40 mg/kg IBW/day IV#&#xD;
Day +5: Begin tacrolimus 0.015mg/kg/ IBW dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35 Discontinue MMF&#xD;
Day +60 Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus&#xD;
Cyclophosphamide: Chemotherapy administration&#xD;
Busulfan: Chemotherapy Administered&#xD;
Unmanipulated Bone Marrow: Bone Marrow Transplant&#xD;
Tacrolimus: Immunosuppressive Drug Administered&#xD;
Mycophenolate mofetil: Immunosuppressive Drug Administered</description>
          </group>
          <group group_id="O2">
            <title>2: Acute Lymphocytic Leukemia/Lymphoma</title>
            <description>Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV+&#xD;
Days -3 through -1: TBI 200 cGy twice a day for 3 days&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV&#xD;
Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35: Discontinue MMF&#xD;
Day +60: Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus&#xD;
Cyclophosphamide: Chemotherapy administration&#xD;
TBI: Radiation Therapy&#xD;
Unmanipulated Bone Marrow: Bone Marrow Transplant&#xD;
Tacrolimus: Immunosuppressive Drug Administered&#xD;
Mycophenolate mofetil: Immunosuppressive Drug Administered</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Donor Cell Engraftment</title>
          <description>Number of Participants with Donor Cell Engraftment at Day 60 following myeloablative, HLA-mismatched BMT.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft Versus Host Disease (GVHD) Grades 2-4 and Grades 3-4</title>
        <description>Number of participants with acute GVHD grades 2-4 and grades 3-4. Acute GVHD Grade 0= no skin, liver or gut involvement; Grade I= Stage 1-2 skin involvement, no liver or gut involvement; Grade II= Stage 3 skin, and/or Stage 1 liver, and/or Stage 1 gut involvement; Grade III= Stage 3 or no skin involvement, Stage 2-3 liver or Stage 2-4 gut involvement; Grade IV= Stage 4 skin or Stage 4 liver involvement. Skin involvement is staged as follows: 1= rash &lt;25% body surface area (BSA), 2= rash 25-50% BSA, 3= rash &gt;50% BSA, 4= generalized erythroderma with bullae. Gastrointestinal (gut) involvement is staged as follows: 1= diarrhea 500-1000 mL/day or 280-555 mL/m^2, or persistent nausea; 2= diarrhea 1000-1499 mL/day or 556-833 mL/m^2; 3= diarrhea &gt;1500 mL/day or &gt;833 mL/m^2; 4= large volume of diarrhea and severe abdominal pain with/without ileus. Liver involvement is staged as follows: 1= bilirubin 2-3mg/dL, 2= bilirubin 3-6mg/dL, 3= 6-15mg/dL, bilirubin &gt;15 mg/dL</description>
        <time_frame>2 Years</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary and Secondary Graft Failure</title>
        <description>Number of participants with primary and secondary graft failure.</description>
        <time_frame>2 Years</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steroid and Non-steroid Immunosuppressants</title>
        <description>Characterize the duration of use, number, and type of steroid and non-steroid immunosuppressants used to treat GVHD.</description>
        <time_frame>Two Years</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Estimate overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), event-free survival, and relapse-free GVHD-free survival (GRFS) in patients receiving myeloablative, HLA-mismatched BMT for patients with high risk hematologic malignancies at 1 year and 2 years.</description>
        <time_frame>up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematologic and Non-hematologic Toxicities</title>
        <description>Assess hematologic and non-hematologic toxicities of myeloablative haploidentical BMT.</description>
        <time_frame>Two Years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution</title>
        <description>Characterize immune reconstitution post myeloablative haploidentical BMT with Post transplantation cyclophosphamide (PT/Cy).</description>
        <time_frame>Two Years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up tp 100 days after transplantation. Mortality was observed for up to 1 year post-intervention.</time_frame>
      <desc>Adverse events reported at each visit during time at transplant center and up to 100 days post-transplantation.</desc>
      <group_list>
        <group group_id="E1">
          <title>1: Acute Lymphoblastic Leukemia/Lymphoma</title>
          <description>Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days*&#xD;
Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV+&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV# Mesna 40 mg/kg IBW/day IV#&#xD;
Day +5: Begin tacrolimus 0.015mg/kg/ IBW dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35 Discontinue MMF&#xD;
Day +60 Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus&#xD;
Cyclophosphamide: Chemotherapy administration&#xD;
Busulfan: Chemotherapy Administered&#xD;
Unmanipulated Bone Marrow: Bone Marrow Transplant&#xD;
Tacrolimus: Immunosuppressive Drug Administered&#xD;
Mycophenolate mofetil: Immunosuppressive Drug Administered</description>
        </group>
        <group group_id="E2">
          <title>2: Acute Lymphocytic Leukemia/Lymphoma</title>
          <description>Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV+&#xD;
Days -3 through -1: TBI 200 cGy twice a day for 3 days&#xD;
Day 0: Infuse unmanipulated bone marrow&#xD;
Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV&#xD;
Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day&#xD;
Day +30 Assess chimerism and disease status in bone marrow&#xD;
Day +35: Discontinue MMF&#xD;
Day +60: Assess chimerism and disease status in bone marrow&#xD;
Day 180 Discontinue tacrolimus&#xD;
Cyclophosphamide: Chemotherapy administration&#xD;
TBI: Radiation Therapy&#xD;
Unmanipulated Bone Marrow: Bone Marrow Transplant&#xD;
Tacrolimus: Immunosuppressive Drug Administered&#xD;
Mycophenolate mofetil: Immunosuppressive Drug Administered</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-occlusive Disease/ Hepatic Sinusoidal Obstruction Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Broviac Cather Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Graft Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Acute GVHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral Mucositis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="12" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>White Blood cells decreased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather Symons, MD</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-502-9961</phone>
      <email>hsymons2@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

